Aclimostat (ZGN-1061) is a highly potent inhibitor of the MetAP2 enzyme that demonstrates promising efficacy and safety profiles in preclinical trials. In a mouse model of obesity and insulin resistance, ZGN-1061 exhibits comparable weight loss efficacy to beloranib, while also improving metabolic parameters. Additionally, ZGN-1061 induces consistent changes in gene transcription in HepG2 cells, further supporting its positive pharmacological effects.
Cefonicid (free base) is a second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
WIN 66306 is a cyclic heptapeptide antagonist of neurokinin-1 (NK1) and NK2 receptors originally isolated from A. flavipes. It binds to NK1 and NK2 receptors and inhibits contractions induced by substance P in isolated guinea pig ileum in a concentration-dependent manner.